ReviewPathologie (Heidelberg, Germany)2026
[Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future].
Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrothelial carcinoma is characterized by pronounced molecular and histological heterogeneity, which significantly influences both its tumorigenesis and therapeutic response. Targeted molecular alterations can be useful tools in everyday pathology for distinguishing between important differential diagnoses and for confirming diagnoses.
aimsThis article aims to provide a brief overview of the diagnostic and predictive molecular changes in urothelial carcinoma and to relate these to therapeutic implications. MATERIAL AND
methodsThis article was written as a narrative overview article. RESULTS AND DISCUSSION: The integration of molecular alterations with histological subtypes and morphological changes enables improved diagnostic accuracy and supports the targeted selection of predictive testing, particularly with regard to FGFR-, HER2-, and PD-(L)1-targeted therapies as well as antibody-drug conjugates.
Indexed as
Identifiers
42059898What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.